Alpha Tau Medical (NASDAQ:DRTS) Stock Price Expected to Rise, HC Wainwright Analyst Says

Posted by Stanley Muller on May 12th, 2026

Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) had its price target increased by analysts at HC Wainwright from $12.00 to $15.00 in a report released on Tuesday, MarketBeat.com reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 45.07% from the stock’s previous close.

DRTS has been the subject of a number of other research reports. Citigroup upped their price target on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Monday, April 20th. Piper Sandler reaffirmed a “neutral” rating and set a $5.00 price target on shares of Alpha Tau Medical in a report on Wednesday, March 4th. Finally, Zacks Research raised shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 17th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $9.67.

Check Out Our Latest Report on Alpha Tau Medical

Alpha Tau Medical Stock Performance

Shares of Alpha Tau Medical stock opened at $10.34 on Tuesday. The company has a 50 day moving average of $7.43 and a 200-day moving average of $6.17. Alpha Tau Medical has a 1-year low of $2.75 and a 1-year high of $10.80. The company has a current ratio of 7.45, a quick ratio of 7.45 and a debt-to-equity ratio of 0.08. The company has a market cap of $910.02 million, a PE ratio of -19.51 and a beta of 1.11.

Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). As a group, equities research analysts forecast that Alpha Tau Medical will post -0.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alpha Tau Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in DRTS. Apella Capital LLC bought a new position in Alpha Tau Medical in the 4th quarter valued at approximately $1,892,000. Daytona Street Capital LLC bought a new position in Alpha Tau Medical in the 4th quarter valued at approximately $749,000. Mariner LLC increased its position in Alpha Tau Medical by 185.8% in the 3rd quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after acquiring an additional 80,129 shares during the period. Millennium Management LLC increased its position in Alpha Tau Medical by 185.7% in the 4th quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock valued at $534,000 after acquiring an additional 70,081 shares during the period. Finally, Bank of America Corp DE increased its position in Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after acquiring an additional 21,677 shares during the period. Institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

(Get Free Report)

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.